Long-acting agonists targeting the glucagon-like peptide-1 receptor (GLP-1R) are the most efficacious treatment to combat the obesity epidemic [see (1–3) for review]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.